Sanofi records €1B+ write-off, ends work on two immunology assets

Sanofi books over €1B in Q2 impairment charges axing amlitelimab, balinatunfib and itepekimab, and upgrades 2026 sales guidance to ~10% growth.

Raccontata daendpoints.news